The medical management of prostate cancer: a multidisciplinary team approach

Sternberg, Cora N.; Krainer, Michael; Oh, William; Bracarda, Sergio; Bellmunt, Joaquim; Ozen, Haluk; Zlotta, Alexandre R.; Beer, Tomasz T.M.; Oudard, Stéphane; Rauchenwald, Michael; Skoneczna, Iwona; Borner, Markus; Fitzpatrick, John M.

doi:10.1111/j.1464-410x.2006.06477.x

Cited by 35 publications

(20 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Re-administration ofdocetaxelhasbeenusedinpatientswithareasonablylong intervalforpreviousdocetaxeltherapy,aswasthecaseinour patient.Second-linechemotherapywithlow-doseintermittent docetaxelhasbeenevaluatedbyOhlmannetal. (reviewedin [12]) in 25 patients previously treated with docetaxel-based chemotherapy. More than 70% had a PSA response (50% decreaseinPSAfrombaseline)thatlastednearly6months.…”

Section: Discussionmentioning

confidence: 99%

Prostate Cancer with Metastasis to the Omentum and Massive Ascites: A Rare Manifestation of a Common Disease

et al. 2009

View full text Add to dashboard Cite

Background: The most common sites of metastasis in prostate cancer include bone and regional lymph nodes followed by lung, liver, and brain. Peritoneal metastasis without skeletal involvement is extremely rare. Case Report: We present herein a patient with hormone refractory prostate cancer with peritoneal metastasis accompanied by ascites but without bone metastasis. The patient initially experienced an excellent response to docetaxelbased chemotherapy. Conclusions: Prostate cancer can present with distant metastasis in unexpected sites. The lack of skeletal involvement does not exclude the possibility of distant metastases. The presence of ascites may indicate peritoneal disease which could be responsive to current standard chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Prostate Cancer with Metastasis to the Omentum and Massive Ascites: A Rare Manifestation of a Common Disease

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Sowohl das Fehlen von Knochenschmerzen (medianes Überleben von 23,0 Monaten beim asymptomatischen vs. 14,9 Monate beim symptomatischen Patienten) als auch ein PSA-Abfall von ≥30% nach 3 Monaten (4 Zyklen Docetaxel) sind mit signifikant längerem Überleben assoziiert [6,37]. Allerdings gibt es auch eine Patientensubgruppe, die trotz geringerem PSAAbfall einen Überlebensbenefit hat [3,26].…”

Section: Chemotherapiestart: Metastasiert Symptomatischunclassified

Rolle der Chemotherapie beim kastrationsresistenten Prostatakarzinom

Santis

Bachner

2012

Urologe

View full text Add to dashboard Cite

Chemotherapy options for the treatment of metastatic castration-resistant prostate cancer (CRPC) have been very limited for many decades. Until 2004, only mitoxantrone was approved, providing palliation, but no survival benefit. With the introduction of docetaxel, the landscape of chemotherapy for CRPC changed substantially. Prednisone and three-weekly docetaxel showed an overall survival (OS) benefit compared to mitoxantrone plus prednisone, in addition to a significant improvement of quality of life and pain reduction. Further strategies to treat CRPC with chemotherapy include reinduction with docetaxel in responding patients and the use of cabazitaxel, a novel semi-synthetic microtubule inhibitor, in the docetaxel-refractory population. This review article is meant to guide physicians through the optimal use of chemotherapy in CRPC patients in daily clinical practice.

show abstract

“…Aufgrund der spezifischen Herausforderungen des hrPC ist ein interdisziplinäres Vorgehen grundsätzlich anzustreben [10].…”

Section: Definition Des Hormonrefraktären Prostatakarzinomsunclassified

“…Bei Wiederaufnahme der Chemotherapie nach den ersten Chemoholidays reagierte die Hälfte der Patienten wiederum mit einem mindestens 50-prozentigen PSA-Abfall. Eine andere Studie [29] untersuchte die Kombination von wöchentlichem Docetaxel mit Estramustin (an den Tagen 1-3, [8][9][10][15][16][17]. Die Therapie wurde nach drei Zyklen unterbrochen, wenn keine Progression vorlag.…”

Section: Evidenzbasierte Chemotherapie Beim Hormonrefraktären Prostatunclassified

Chemotherapy for prostate cancer

Rauchenwald

Santis

Fink³

et al. 2008

Wien Klin Wochenschr

Self Cite

View full text Add to dashboard Cite

For many years the benefit of chemotherapy in patients with prostate cancer was thought to be limited to palliation of late-stage disease, and thus this treatment option only became involved in patient care towards the end of the disease process, if at all. However, two landmark phase-III trials with docetaxel-based therapy (TAX 327 and Southwest Oncology Group, SWOG, 9916) have shown a survival benefit for patients with hormone refractory prostate cancer (HRPC) thus prompting a change in patterns of care. With raising interest for chemotherapeutic options and clinical trials for new drugs and new indications (neoadjuvant therapy, adjuvant therapy, increasing PSA levels after local treatment, and hormone sensitive cancer) under way our goal was to review within the context of a multidisciplinary team the available evidence and explore the standard for the medical treatment of prostate cancer outside of clinical trials. We are carefully evaluating the current treatment recommendations based on the available evidence and highlight potential future treatment options but also discuss important clinical topics (treatment until progression versus the advantage of chemo holidays, definition of particular patient subgroups and potential second line options) for which there are no clear cut answers to date. The role and importance of radiotherapy, biphosphonate treatment and the medical management of pain and side effects is also discussed. The multitude of treatment options for patients with advanced prostate cancer clearly asks for a close collaboration between urologists, medical oncologists and radiation therapists.

show abstract

The medical management of prostate cancer: a multidisciplinary team approach

Cited by 35 publications

References 34 publications

Prostate Cancer with Metastasis to the Omentum and Massive Ascites: A Rare Manifestation of a Common Disease

Prostate Cancer with Metastasis to the Omentum and Massive Ascites: A Rare Manifestation of a Common Disease

Rolle der Chemotherapie beim kastrationsresistenten Prostatakarzinom

Chemotherapy for prostate cancer

Contact Info

Product

Resources

About